Connect with us

News

Celebrity-backed longevity start-up closes US$10m seed round

John Legend, Chrissy Teigen, Pedro Pascal and Zac Efron are among the celebrities who have individually invested in the company

Published

on

A US biotech start-up, backed by John Legend, Chrissy Teigen and Zac Efron, has secured US$10m in funding to “change” the way people age.

Tally Health, founded by Dr David Sinclair and serial entrepreneur Whitney Casey, aims to improve healthspan and extend longevity at the cellular level using epigenetic age tests, personalised lifestyle recommendations and longevity supplements.

The new capital, the New York-based company says, will support the research and development of new products, additional features, and technology integrations to allow users to integrate the feedback of their epigenetic age test into their daily lifestyle digitally.

“This financing underscores the significant and growing consumer interest in healthspan and longevity,” said Melanie Goldey, CEO of Tally Health.

“I am pleased to see our 270,000+ pre-launch waitlist converting as we attract new members, investors, and celebrities who believe in our mission to increase healthspan, drive impactful lifestyle changes, and extend human healthspan and longevity.”

Consumer interest in the longevity space has exploded in recent years, with the global longevity economy projected to reach an astounding US$27t in 2026 and the agetech segment reaching US$2.7t by 2025, according to Longevity Technology.

Kirsten Green, founding partner at Forerunner Ventures, which led the funding round, said: “Longevity presents a remarkable, untapped opportunity, particularly in the context of its fundamental, universal importance — everyone ages, and increasingly savvy, health-conscious generations are highly motivated to have more agency over the process and ultimately live a more fulfilling life.

“The Tally Health team is in a category-defining position to open up access to scientific breakthroughs that not just slow aging, but can even help reverse it.”

Celebrities including John Legend, Chrissy TeigenPedro Pascal, Shonda Rhimes, Kevin HartRich RollWhitney Cummings, and Zac Efron have individually invested in the longevity start-up.

Whitney Casey, co-founder of Tally Health and partner at L Catterton, said: “We founded Tally Health based on pure demand for more science-backed longevity innovations for consumers.

“We are able to scale learnings from breakthrough epigenetic research with our own proprietary technologies to bring the science in-home for our members.

“There is a growing global consumer interest in evaluating health through the lens of longevity, and Tally Health’s continued growth will propel the agetech sector forward.”

Diagnosis

Millions of women with breast cancer could be spared chemo with genomic test

Published

on

A genomic test may help some women with breast cancer avoid chemotherapy, with near-identical outcomes in an international trial.

The findings suggest patients with a low test score could be treated with hormone therapy alone without increasing the risk of their cancer returning.

Researchers said the results could support more personalised treatment decisions and spare some women the side-effects of chemotherapy.

Prof Rob Stein, the trial’s chief investigator and a professor of breast oncology at UCL, said: “Optima addresses a longstanding challenge in breast cancer care: identifying who truly benefits from chemotherapy and who does not.

“Our findings show that many patients can safely avoid chemotherapy without compromising their outcomes.

“These results mark an important and significant step toward more personalised treatment.

“The trial has successfully used tumour biology to guide decisions rather than relying solely on traditional clinical features.”

Breast cancer treatment usually involves surgery to remove tumours. Chemotherapy is then often recommended if doctors believe there is a risk the disease will return.

Chemotherapy can cause side-effects including hair loss, rashes, nausea, insomnia and fatigue. Some women may also face longer-term consequences such as infertility, cognitive impairment or early menopause.

The Optima trial followed more than 4,000 patients with newly diagnosed breast cancer in the UK, Norway, Sweden, Australia, New Zealand and Thailand.

The trial was led by University College London.

One woman who took part in the trial told the Guardian that being able to skip chemotherapy felt “like Christmas”. Nine years after being diagnosed, taking the test and skipping chemotherapy, she is healthy and enjoying a full and active life.

The trial tested whether a genomic test could identify which patients need chemotherapy and which could safely avoid it.

The Prosigna test, made by diagnostics company Veracyte, analyses the activity of 50 genes in tumour tissue. It identifies the molecular subtype of the cancer and gives a score estimating the risk of breast cancer returning in the next 10 years.

The randomised trial involved 4,429 patients aged 40 or over with hormone-positive breast cancer. Hormone-positive breast cancer grows in response to hormones such as oestrogen or progesterone. It is the most common form of breast cancer, accounting for up to 80 per cent of cases globally.

Participants were assigned to one of two groups. In the standard treatment group, patients received chemotherapy followed by hormone therapy.

In the second group, patients had their tumours analysed using the genomic test. Those with a high score received chemotherapy and hormone therapy. Those with a low score received hormone therapy alone.

Radiotherapy and other treatments were given as usual in both groups.

In the second group, outcomes were very similar whether chemotherapy was given or not. Five years after treatment, 95 per cent of patients who had chemotherapy and hormone therapy were alive and free from breast cancer recurrence, while 94 per cent of those who skipped chemotherapy were also alive and recurrence-free.

The findings suggest chemotherapy offered little or no additional benefit for patients with low test scores.

Some men also took part in the study, but researchers said there were too few to draw firm conclusions for this group.

The trial received funding from the National Institute for Health and Care Research, Veracyte and cancer charities.

Prof Iain MacPherson, a co-chief investigator and professor of breast oncology at the University of Glasgow, said: “Optima provides robust, practice-changing evidence that we can safely reduce the use of chemotherapy for many patients with hormone-sensitive breast cancer.

“These findings represent a major step forward in delivering more personalised, precise care, ensuring that treatment decisions are driven by what will genuinely improve outcomes for patients, while avoiding unnecessary toxicity.

“The potential impact for both patients and health services is substantial.”

Continue Reading

Hormonal health

Iron deficiency in women: The tiredness everyone normalises

Published

on

Article produced in association with Spital Clinic

Feeling permanently tired has become so normal for so many women that most of us have stopped questioning it. But one of the most common reasons behind it is also one of the easiest to miss – and one of the most satisfying to fix.

The tiredness that gets explained away

There’s a particular kind of tired that a lot of women simply live with. The mid-afternoon slump that no amount of coffee touches. Needing an early night and still waking up flat. Putting it all down to work, kids, stress, age or hormones – anything except a cause you could actually do something about.

Often, though, that’s exactly what it is: a cause you could do something about. Low iron is one of the most common reasons women feel wiped out, and because it builds so gradually, it rarely announces itself. You don’t wake up one morning feeling different. You just slowly get used to running on less, until “exhausted” starts to feel like your baseline.

Why women are far more likely to run low

Iron is what your body uses to carry oxygen around in your blood. When levels fall, everything has to work a little harder to do the same job – which is why feeling tired is usually the very first thing you notice.

The reason this affects women so disproportionately is simple: periods. Every cycle carries a small iron cost, and over months and years that quietly adds up. Pregnancy adds to the demand too, when the body’s iron needs rise sharply.

But heavy periods are the big one – left unchecked, they can steadily drain your iron, which is why the NHS treats them as something worth looking into rather than just putting up with.

So if your periods sit on the heavier side, you’re not just dealing with the inconvenience in the moment – you may be slowly draining your iron stores at the same time, month after month.

The reassuring part is that heavy periods can be treated, so it’s worth having them looked at rather than soldiering on.

What low iron actually feels like

Tiredness is the headline, but it’s rarely the only clue. Low iron can show up as feeling breathless going up stairs you used to manage without thinking, a foggy, can’t-quite-focus feeling, looking paler than usual, or noticing your heart racing or thumping for no obvious reason.

Then there are the stranger signs people almost never connect to iron: brittle nails, more hair than usual collecting in the brush, restless legs at night, and – oddly – craving and crunching ice. On their own, each of these is easy to shrug off. Lined up together, they’re very often the same story.

Why it so often slips under the radar

Part of the problem is that none of these symptoms screams “iron.” They’re vague, they overlap with ordinary life, and they arrive slowly enough that you adjust without realising. Most of us are also remarkably good at minimising our own tiredness – we assume everyone feels like this, so there’s nothing to mention.

The result is that low iron can go unaddressed for years, not because it’s hard to find, but because nobody thinks to look. It’s a genuinely common, genuinely treatable issue that quietly chips away at how good you’re allowed to feel.

When “heavy” periods are actually heavy

Here’s the tricky bit: most women have no real benchmark for what counts as heavy, because the only period we ever experience is our own. A useful rule of thumb is needing to change a pad or tampon every hour or two, bleeding that lasts longer than seven days, or passing clots bigger than a 10p coin.

NICE frames it even more usefully: periods count as heavy if they’re getting in the way of your life – physically, emotionally or socially. You don’t have to measure anything. If you’re planning your week around your period, doubling up on protection, or it’s leaving you drained, that’s reason enough to take it seriously.

And the good part is they don’t have to be permanent. If yours have crept up over time, getting them under control is worth it in its own right – and it often tackles the iron problem at its source, rather than topping you up only to lose it again next month.

How you actually find out

You can’t tell your iron levels from how you feel. Plenty of women feel rough with results that look “borderline fine,” and some feel reasonably okay while their reserves are already running low.

The only way to know is a straightforward blood test that checks both your blood count and your ferritin – the marker that reflects how much iron you’ve actually got stored away.

Ferritin is the one that matters here, because it tends to drop first, before a standard anaemia test would flag anything as wrong. That’s exactly why a woman can be told her bloods are “normal” and still feel exhausted: the headline number looks acceptable, but the reserves sitting behind it have been running down for a while.

The good news: it’s very fixable

This is the part worth holding onto. Iron deficiency is one of the more rewarding things to put right. The NHS approach is usually a course of iron tablets over several months to rebuild your stores, paired with a source of vitamin C – even just a glass of orange juice – to help your body absorb them properly.

Alongside that, dealing with whatever’s causing the loss in the first place is what stops you ending up back at square one.

Most women start to notice the difference within a few weeks, often well before their levels are fully restored. The fog lifts, the stairs get easier, and the version of “normal” you’d quietly resigned yourself to turns out not to have been normal at all.

The takeaway

The exhaustion so many women treat as a fixed fact of life frequently isn’t one. Low iron is common, it’s quick to check, and it’s straightforward to put right – but only if someone actually looks for it.

If you’ve been tired for longer than you can remember, especially if your periods are heavy, it’s worth getting your iron checked rather than explaining it away for another year. Speaking to a GP is usually all it takes to get that started – and more often than not, the fix turns out to be far simpler than the months of tiredness would suggest.

Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment. Clinical guidance referenced reflects published NHS and NICE information as at May 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article. This piece was produced in association with Spital Clinic, which provided background clinical information for editorial purposes. Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.

Continue Reading

Hormonal health

Supermarket receipts shine light on ‘sheer scale and impact of menstrual pain’

Published

on

Supermarket loyalty card data suggests more than a quarter of women buying menstrual products also buy pain relief at the same time.

The findings also suggest women in lower-income areas are significantly less likely to do so, pointing to disparities in access to over-the-counter pain relief across England.

The study was led by Dr Victoria Sivill of the University of Bristol and colleagues.

The authors said: “The study highlights the need for greater awareness and policy interventions to address the high prevalence of menstrual pain as well as socioeconomic dimensions of menstrual pain.

“Public health initiatives should incorporate menstrual pain relief as part of broader efforts to improve health equity.”

Researchers analysed anonymised loyalty card data from a major UK health and beauty retailer, covering 211m transactions by 3.4m people between 2006 and 2015.

The study examined how often shoppers bought menstrual products and pain relief in the same transaction, and compared this with a customer’s usual rate of buying pain relief.

It found that 26.7 per cent of customers who bought menstrual products also bought pain relief at the same time.

These customers were nearly four times more likely to buy pain relief when buying menstrual products than on other shopping trips.

As a check on the approach, researchers found the most common interval between consecutive menstrual product purchases was exactly 28 days, consistent with the average menstrual cycle.

Menstrual pain is common and can affect daily activities, including school and work attendance.

Regional income was the strongest predictor of menstrual pain purchases.

Customers in the lowest-income areas were 32 per cent less likely to buy pain relief at the same time as menstrual products than those in the highest-income areas.

The authors said lower rates of pain relief purchases in deprived areas are likely to reflect an inability to afford over-the-counter medication rather than lower rates of menstrual pain itself.

Co-author Dr James Goulding said: “It is wonderful that smart data research in the UK is able to bring issues which may have once been overlooked in scientific settings, such as the sheer scale and impact of menstrual pain, to light. This is well overdue.

Co-author Dr Anya Skatova said: “Like many women, I was aware of how common menstrual pain is, but the scale of painkiller purchases alongside menstrual products was still striking.

“Using shopping data, we can see just how widespread the need for pain relief really is. This kind of evidence helps make menstrual pain visible at a population level and provides a strong foundation for systemic change in how it is recognised, treated, and prioritised in public health.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.